醫藥相關股造好 麗珠(01513.HK)威高(01066.HK)愛康(01789.HK)漲約5%-6%破頂
港股今早高開123點或0.5%報24,503欠承接,曾倒跌154點低見24,225拒絕再下,現造24,396,反覆續彈16點,成交額365億元。
不過,部分醫藥股受捧,其中愛康醫療(01789.HK)承上周五回吐勢,今早股價低開0.7%,見20.4元獲承接,掉頭高見22.4元,再創上市新高,現造21.9元,倒升6%,成交達572萬股,已接近上周五全日成交量701萬股。愛康本月上旬公布,以現金總代價4,020萬美元,向獨立第三方美敦力康輝收購主要於內地從事產售及研究骨科植入物及手術器械的北京理貝爾全部股權。另外,該公司3月下旬公布,去年純利按年急增84%至2.67億人民幣(下同),每股盈利26分,末期股息按年增1.1倍至7.5港仙(6月18日除淨)。期內,總收入按年增逾54%至9.27億元;毛利按年增逾57%至6.43億元。
此外,綠葉製藥(02186.HK)及威高股份(01066.HK)升5%-6%,後者曾升破3月所創紀錄高位11.76元,最高見11.88元。
藥明生物(02269.HK)、阿里健康(00241.HK)、藍籌中生製藥(01177.HK)、平安好醫生(01833.HK)、春立醫療(01858.HK)、藥明生物(02269.HK)、藥明康德(02359.HK)、康希諾生物-B(06185.HK)、復星醫藥(02196.HK)及麗珠醫藥(01513.HK)升逾2.5%-4.5%,後兩者升幅最大分別報28.5元及33元,後者升近半成創近兩年高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.